...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
【24h】

In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.

机译:静脉内给药后,硫代磷酸酯寡核苷酸在大鼠肝脏内的体内分布和代谢。

获取原文
获取原文并翻译 | 示例
           

摘要

In the rat, the liver represents a major site of phosphorothioate oligodeoxynucleotide deposition after i.v. administration. For this reason, we examined the intracellular fate of ISIS 1082, a 21-base heterosequence phosphorothioate oligodeoxynucleotide, isolated from parenchymal and nonparenchymal cell types after systemic dosing using established perfusion and separation techniques followed by CGE. Isolated cells were further fractionated into nuclear, cytosolic and membrane constituents to assess the intracellular localization, distribution and metabolic profiles as a function of time and dose. After a 10-mg/kg i.v. bolus, intracellular drug levels where maximal after 8 hr and diminished significantly thereafter, suggesting an active efflux mechanism or metabolism. Nonparenchymal (i.e., Kupffer and endothelial) cells contained approximately 80% of the total organ cellular dose, and this was equivalently distributed between the two cell types, while the remaining 20% was associated with hepatocytes. Nonparenchymal cells contained abundant nuclear, cytosolic and membrane drug levels over a wide dose range. In contrast, at doses of less than 25 mg/kg, hepatocytes contained significantly less drug with no detectable nuclear-association. Doses at or above 25 mg/kg appeared to saturate nonparenchymal cell types, whereas hepatocytes continued to accumulate drug in all cellular compartments, including the nucleus. Our results suggest that although pharmacokinetic parameters vary as a function of hepatic cell type, significant intracellular delivery can be readily achieved in the liver after systemic administration.
机译:在大鼠中,静脉内注射后,肝脏代表了硫代磷酸酯寡脱氧核苷酸沉积的主要部位。行政。由于这个原因,我们检查了ISIS 1082的细胞内命运,ISIS 1082是21碱基的异硫代磷酸酯寡聚脱氧核苷酸,使用既有的灌流和分离技术,然后使用CGE,从全身和非实质细胞类型中分离出来。将分离的细胞进一步分为核,胞质和膜成分,以评估细胞内的定位,分布和代谢谱随时间和剂量的变化。静脉注射10毫克/千克后推注时,细胞内药物水平在8小时后达到最大值,此后显着降低,表明存在主动外排机制或新陈代谢。非实质细胞(即枯否细胞和内皮细胞)约占总器官细胞剂量的80%,这在两种细胞类型之间均等分布,而其余20%与肝细胞有关。非实质细胞在很宽的剂量范围内含有丰富的核,胞质和膜药物水平。相反,在小于25 mg / kg的剂量下,肝细胞所含药物明显减少,并且没有可检测到的核缔合。剂量等于或高于25 mg / kg似乎会使非实质细胞类型饱和,而肝细胞则继续在包括核在内的所有细胞区室中积聚药物。我们的结果表明,尽管药代动力学参数随肝细胞类型的变化而变化,但全身性给药后,肝脏中很容易实现明显的细胞内递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号